Advocacy intelligence hub — real-time data for patient organizations
Paradigm Therapeutics — PHASE3
Paradigm Therapeutics — PHASE3
RHEACELL GmbH & Co. KG — PHASE3
RHEACELL GmbH & Co. KG — PHASE3
Assistance Publique - Hôpitaux de Paris — NA
Institut National de la Santé Et de la Recherche Médicale, France — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Aminocaproic Acid
(AMINOCAPROIC ACID)Orphan drugstandardAmerican Regent, Inc.
Antifibrinolytic Agent [EPC]
Alain Hovnanian, Prof
National Institut of health and medical research
Elena Pope, MD, OTR
The Hospital for Sick Children
📍 SANTA FE, NM
Su Chan Kim, PhD
Gangnam Severence Hospital
David Woodley, MD, RN
University of Southern California Department of Dermatology
📍 BUFFALO, NY
Jean Tang, MD, Ph.D., ARNP
Stanford University
📍 SEATTLE, WA
Jean Tang, MD, PhD, Ph.D., ARNP
Stanford University
📍 SEATTLE, WA